| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Factor Xa Inhibitors | 4 | 2021 | 70 | 2.750 |
Why?
|
| Respiratory Syncytial Virus, Human | 11 | 2023 | 211 | 2.050 |
Why?
|
| Respiratory Syncytial Virus Infections | 16 | 2023 | 427 | 1.860 |
Why?
|
| Blood Coagulation Factors | 3 | 2021 | 59 | 1.650 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 7 | 2021 | 55 | 1.530 |
Why?
|
| Intracranial Hemorrhages | 2 | 2021 | 121 | 1.470 |
Why?
|
| Warfarin | 2 | 2019 | 152 | 1.290 |
Why?
|
| Hemorrhage | 3 | 2019 | 712 | 1.110 |
Why?
|
| Anticoagulants | 3 | 2020 | 787 | 1.050 |
Why?
|
| Palivizumab | 4 | 2023 | 64 | 1.030 |
Why?
|
| Viral Fusion Proteins | 6 | 2021 | 85 | 1.020 |
Why?
|
| Hypokalemia | 1 | 2023 | 55 | 0.910 |
Why?
|
| Antidotes | 2 | 2021 | 28 | 0.890 |
Why?
|
| Thrombelastography | 2 | 2021 | 79 | 0.830 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2023 | 136 | 0.820 |
Why?
|
| Rivaroxaban | 1 | 2021 | 59 | 0.780 |
Why?
|
| Hyperglycemia | 1 | 2023 | 333 | 0.750 |
Why?
|
| Antibodies, Neutralizing | 9 | 2023 | 541 | 0.740 |
Why?
|
| Antiviral Agents | 10 | 2018 | 1230 | 0.730 |
Why?
|
| Sigmodontinae | 12 | 2023 | 38 | 0.700 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2021 | 163 | 0.700 |
Why?
|
| Factor Xa | 1 | 2019 | 26 | 0.690 |
Why?
|
| Neurosurgery | 1 | 2020 | 108 | 0.680 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2019 | 66 | 0.670 |
Why?
|
| Craniocerebral Trauma | 1 | 2020 | 130 | 0.670 |
Why?
|
| Brain Concussion | 1 | 2020 | 194 | 0.620 |
Why?
|
| Pyridones | 1 | 2019 | 348 | 0.580 |
Why?
|
| Pyrazoles | 3 | 2019 | 1471 | 0.520 |
Why?
|
| Respiratory Syncytial Viruses | 6 | 2016 | 171 | 0.510 |
Why?
|
| Aerosols | 10 | 2017 | 158 | 0.500 |
Why?
|
| Recombinant Proteins | 3 | 2019 | 2927 | 0.500 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 1054 | 0.490 |
Why?
|
| Antibodies, Viral | 12 | 2022 | 1320 | 0.490 |
Why?
|
| Orthomyxoviridae Infections | 4 | 2014 | 72 | 0.470 |
Why?
|
| Drug Resistance, Viral | 4 | 2023 | 71 | 0.450 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 2 | 2017 | 152 | 0.440 |
Why?
|
| Stroke | 1 | 2021 | 1144 | 0.420 |
Why?
|
| Adjuvants, Immunologic | 2 | 2018 | 657 | 0.380 |
Why?
|
| Ribavirin | 2 | 2009 | 178 | 0.370 |
Why?
|
| International Normalized Ratio | 2 | 2019 | 48 | 0.360 |
Why?
|
| Haemophilus Infections | 1 | 2009 | 103 | 0.330 |
Why?
|
| Haemophilus influenzae | 1 | 2009 | 144 | 0.320 |
Why?
|
| Lung | 8 | 2023 | 3151 | 0.320 |
Why?
|
| Pneumonia | 2 | 2017 | 751 | 0.320 |
Why?
|
| Influenza, Human | 3 | 2014 | 925 | 0.310 |
Why?
|
| Immunity, Humoral | 2 | 2021 | 86 | 0.300 |
Why?
|
| Camptothecin | 3 | 2004 | 517 | 0.270 |
Why?
|
| Disease Models, Animal | 8 | 2019 | 7222 | 0.250 |
Why?
|
| Animals | 32 | 2023 | 59536 | 0.230 |
Why?
|
| Administration, Inhalation | 6 | 2015 | 285 | 0.210 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2013 | 3251 | 0.200 |
Why?
|
| Influenza A virus | 3 | 2013 | 270 | 0.200 |
Why?
|
| Platelet Function Tests | 1 | 2021 | 50 | 0.200 |
Why?
|
| Fibrin Clot Lysis Time | 1 | 2021 | 1 | 0.200 |
Why?
|
| Rabies Vaccines | 1 | 2021 | 11 | 0.200 |
Why?
|
| Rabies | 1 | 2021 | 16 | 0.200 |
Why?
|
| ADP Ribose Transferases | 1 | 2020 | 28 | 0.190 |
Why?
|
| Humans | 35 | 2023 | 261506 | 0.190 |
Why?
|
| Immunity, Innate | 2 | 2019 | 677 | 0.190 |
Why?
|
| Blood Coagulation | 1 | 2021 | 185 | 0.180 |
Why?
|
| Prothrombin | 1 | 2019 | 36 | 0.180 |
Why?
|
| Vaccines, Attenuated | 2 | 2016 | 210 | 0.180 |
Why?
|
| Liposomes | 7 | 2009 | 684 | 0.170 |
Why?
|
| Bacterial Toxins | 1 | 2020 | 228 | 0.170 |
Why?
|
| Aluminum Compounds | 1 | 2018 | 17 | 0.170 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 709 | 0.170 |
Why?
|
| Hypoglycemic Agents | 1 | 2023 | 586 | 0.170 |
Why?
|
| Antibody Affinity | 1 | 2018 | 61 | 0.170 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2020 | 233 | 0.170 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2019 | 63 | 0.160 |
Why?
|
| STAT6 Transcription Factor | 1 | 2018 | 67 | 0.160 |
Why?
|
| Phosphates | 1 | 2018 | 187 | 0.160 |
Why?
|
| Oseltamivir | 1 | 2017 | 33 | 0.160 |
Why?
|
| Virus Internalization | 2 | 2015 | 88 | 0.160 |
Why?
|
| Lipopeptides | 1 | 2017 | 114 | 0.150 |
Why?
|
| Benzimidazoles | 2 | 2015 | 428 | 0.150 |
Why?
|
| Insulin | 1 | 2023 | 1454 | 0.150 |
Why?
|
| STAT5 Transcription Factor | 1 | 2018 | 214 | 0.150 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 383 | 0.150 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2017 | 261 | 0.150 |
Why?
|
| Vitamin E | 2 | 2009 | 136 | 0.150 |
Why?
|
| Male | 14 | 2021 | 123000 | 0.150 |
Why?
|
| Toll-Like Receptor 6 | 2 | 2017 | 30 | 0.140 |
Why?
|
| Treatment Outcome | 6 | 2021 | 32848 | 0.140 |
Why?
|
| Orthomyxoviridae | 1 | 2016 | 94 | 0.140 |
Why?
|
| Toll-Like Receptors | 1 | 2017 | 174 | 0.140 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 29902 | 0.140 |
Why?
|
| Small Molecule Libraries | 1 | 2018 | 169 | 0.140 |
Why?
|
| Mice | 18 | 2020 | 34495 | 0.140 |
Why?
|
| Toll-Like Receptor 9 | 2 | 2017 | 78 | 0.140 |
Why?
|
| Toll-Like Receptor 2 | 2 | 2017 | 87 | 0.140 |
Why?
|
| Sulfonamides | 2 | 2015 | 1823 | 0.140 |
Why?
|
| Epitopes | 1 | 2018 | 685 | 0.140 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 483 | 0.140 |
Why?
|
| Single-Domain Antibodies | 1 | 2015 | 12 | 0.140 |
Why?
|
| Vaccination | 2 | 2021 | 1123 | 0.140 |
Why?
|
| Virus Attachment | 1 | 2015 | 42 | 0.130 |
Why?
|
| Cell Line | 7 | 2018 | 5114 | 0.130 |
Why?
|
| Nebulizers and Vaporizers | 2 | 2008 | 70 | 0.130 |
Why?
|
| Retroviridae Proteins, Oncogenic | 1 | 2014 | 36 | 0.130 |
Why?
|
| Rats | 3 | 2018 | 6086 | 0.120 |
Why?
|
| TNF Receptor-Associated Factor 3 | 1 | 2013 | 22 | 0.120 |
Why?
|
| Drug Carriers | 2 | 2014 | 327 | 0.120 |
Why?
|
| alpha-Tocopherol | 2 | 2004 | 78 | 0.120 |
Why?
|
| Nanoparticles | 1 | 2018 | 554 | 0.120 |
Why?
|
| Viral Envelope Proteins | 1 | 2015 | 207 | 0.120 |
Why?
|
| RNA, Viral | 1 | 2016 | 671 | 0.120 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2013 | 76 | 0.120 |
Why?
|
| Female | 17 | 2023 | 141928 | 0.110 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 2009 | 494 | 0.110 |
Why?
|
| Germinal Center | 1 | 2013 | 161 | 0.110 |
Why?
|
| Aged | 6 | 2021 | 70117 | 0.110 |
Why?
|
| Polysaccharides | 1 | 2014 | 197 | 0.110 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2013 | 73 | 0.110 |
Why?
|
| Autophagy | 2 | 2020 | 927 | 0.110 |
Why?
|
| Drug Discovery | 1 | 2015 | 324 | 0.100 |
Why?
|
| Immunologic Memory | 1 | 2014 | 374 | 0.100 |
Why?
|
| Mice, Inbred BALB C | 5 | 2016 | 2314 | 0.100 |
Why?
|
| Genetic Vectors | 2 | 2014 | 1694 | 0.090 |
Why?
|
| Asthma | 1 | 2018 | 871 | 0.090 |
Why?
|
| Paclitaxel | 3 | 2009 | 1996 | 0.090 |
Why?
|
| Adenoviridae | 2 | 2014 | 1459 | 0.090 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2013 | 673 | 0.090 |
Why?
|
| Rotenone | 1 | 2009 | 35 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 2403 | 0.090 |
Why?
|
| Wound Healing | 1 | 2014 | 815 | 0.090 |
Why?
|
| Antineoplastic Agents | 4 | 2009 | 14289 | 0.080 |
Why?
|
| B-Lymphocytes | 1 | 2014 | 1294 | 0.080 |
Why?
|
| Macrophages | 1 | 2014 | 1304 | 0.080 |
Why?
|
| Lung Neoplasms | 6 | 2009 | 11538 | 0.080 |
Why?
|
| Transcriptome | 1 | 2016 | 1859 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 3 | 2018 | 503 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2330 | 0.080 |
Why?
|
| Pneumonia, Bacterial | 1 | 2009 | 130 | 0.080 |
Why?
|
| Macrophages, Alveolar | 2 | 2019 | 67 | 0.080 |
Why?
|
| Injections, Intramuscular | 2 | 2021 | 255 | 0.080 |
Why?
|
| Interferons | 1 | 2009 | 291 | 0.080 |
Why?
|
| Dogs | 2 | 2015 | 1155 | 0.070 |
Why?
|
| Dendritic Cells | 1 | 2013 | 1085 | 0.070 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2009 | 852 | 0.070 |
Why?
|
| Proteins | 1 | 2014 | 1963 | 0.070 |
Why?
|
| Fullerenes | 1 | 2005 | 10 | 0.070 |
Why?
|
| Gene Expression | 2 | 2015 | 3570 | 0.070 |
Why?
|
| Tetrazoles | 1 | 2005 | 106 | 0.060 |
Why?
|
| Benzhydryl Compounds | 1 | 2005 | 85 | 0.060 |
Why?
|
| Phenols | 1 | 2005 | 107 | 0.060 |
Why?
|
| Administration, Oral | 3 | 2017 | 1544 | 0.060 |
Why?
|
| Structure-Activity Relationship | 2 | 2018 | 931 | 0.060 |
Why?
|
| Inflammation | 1 | 2014 | 2522 | 0.060 |
Why?
|
| Neutralization Tests | 2 | 2015 | 299 | 0.060 |
Why?
|
| Genes, ras | 2 | 2009 | 667 | 0.060 |
Why?
|
| Viral Load | 2 | 2016 | 493 | 0.060 |
Why?
|
| Pneumonia, Viral | 1 | 2012 | 715 | 0.060 |
Why?
|
| Indazoles | 2 | 2015 | 297 | 0.060 |
Why?
|
| Risk Factors | 1 | 2020 | 17523 | 0.060 |
Why?
|
| Cyclosporine | 1 | 2004 | 278 | 0.050 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2004 | 221 | 0.050 |
Why?
|
| Immunoglobulins | 1 | 2023 | 266 | 0.050 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2002 | 142 | 0.050 |
Why?
|
| Toxicity Tests | 1 | 2002 | 50 | 0.050 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2015 | 994 | 0.050 |
Why?
|
| Urinalysis | 1 | 2002 | 84 | 0.050 |
Why?
|
| Administration, Intranasal | 2 | 2014 | 190 | 0.050 |
Why?
|
| Blood Chemical Analysis | 1 | 2002 | 118 | 0.050 |
Why?
|
| Neoplasm Metastasis | 2 | 2009 | 5112 | 0.050 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2021 | 12 | 0.050 |
Why?
|
| Mutation | 2 | 2018 | 15179 | 0.050 |
Why?
|
| Injections, Intradermal | 1 | 2021 | 58 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2023 | 829 | 0.050 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2014 | 242 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2021 | 383 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2014 | 1489 | 0.050 |
Why?
|
| Seasons | 1 | 2022 | 340 | 0.050 |
Why?
|
| Organ Size | 1 | 2002 | 690 | 0.050 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 3869 | 0.050 |
Why?
|
| Molecular Structure | 2 | 2015 | 515 | 0.040 |
Why?
|
| Solvents | 1 | 2019 | 66 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2015 | 4938 | 0.040 |
Why?
|
| Smoke | 1 | 2019 | 60 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2013 | 3341 | 0.040 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2019 | 252 | 0.040 |
Why?
|
| Phospholipids | 1 | 2019 | 177 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2023 | 698 | 0.040 |
Why?
|
| Respiratory Mucosa | 1 | 2019 | 206 | 0.040 |
Why?
|
| Piperidines | 1 | 2003 | 1035 | 0.040 |
Why?
|
| Pulmonary Emphysema | 1 | 2019 | 145 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2009 | 11965 | 0.040 |
Why?
|
| Kinetics | 1 | 2021 | 2049 | 0.040 |
Why?
|
| Adult | 6 | 2022 | 77950 | 0.040 |
Why?
|
| src Homology Domains | 1 | 2018 | 124 | 0.040 |
Why?
|
| Cell Line, Tumor | 5 | 2016 | 14551 | 0.040 |
Why?
|
| Nicotine | 1 | 2019 | 244 | 0.040 |
Why?
|
| Body Weight | 1 | 2002 | 1293 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2019 | 37905 | 0.040 |
Why?
|
| Drug Stability | 1 | 2016 | 105 | 0.040 |
Why?
|
| Reverse Genetics | 1 | 2016 | 18 | 0.040 |
Why?
|
| Vero Cells | 1 | 2016 | 143 | 0.040 |
Why?
|
| Pyridines | 1 | 2003 | 1244 | 0.040 |
Why?
|
| Protein Engineering | 1 | 2016 | 100 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2017 | 553 | 0.030 |
Why?
|
| Cell Fusion | 1 | 2015 | 80 | 0.030 |
Why?
|
| Pichia | 1 | 2015 | 60 | 0.030 |
Why?
|
| Respiratory System | 1 | 2016 | 125 | 0.030 |
Why?
|
| Peptides | 1 | 2021 | 1479 | 0.030 |
Why?
|
| Temperature | 1 | 2016 | 506 | 0.030 |
Why?
|
| Leukocyte Reduction Procedures | 1 | 2014 | 7 | 0.030 |
Why?
|
| Drug Synergism | 2 | 2012 | 1313 | 0.030 |
Why?
|
| Ligands | 1 | 2017 | 995 | 0.030 |
Why?
|
| Macaca fascicularis | 1 | 2015 | 137 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2002 | 1616 | 0.030 |
Why?
|
| Nasal Cavity | 1 | 2015 | 149 | 0.030 |
Why?
|
| Complement C1q | 1 | 2014 | 28 | 0.030 |
Why?
|
| Mutant Proteins | 1 | 2015 | 234 | 0.030 |
Why?
|
| Chromatography, Gas | 1 | 2013 | 39 | 0.030 |
Why?
|
| Homeostasis | 1 | 2019 | 950 | 0.030 |
Why?
|
| Receptors, Fc | 1 | 2014 | 69 | 0.030 |
Why?
|
| Infant | 2 | 2023 | 13310 | 0.030 |
Why?
|
| Oligonucleotide Probes | 1 | 2013 | 130 | 0.030 |
Why?
|
| Osteopontin | 1 | 2014 | 148 | 0.030 |
Why?
|
| Fibronectins | 1 | 2014 | 197 | 0.030 |
Why?
|
| Viral Proteins | 1 | 2016 | 435 | 0.030 |
Why?
|
| Bronchi | 1 | 2015 | 326 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2020 | 1546 | 0.030 |
Why?
|
| Middle Aged | 2 | 2019 | 86204 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2013 | 191 | 0.030 |
Why?
|
| High-Throughput Screening Assays | 1 | 2015 | 216 | 0.030 |
Why?
|
| Mice, Inbred C3H | 2 | 2004 | 385 | 0.030 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2013 | 33 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2014 | 360 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 6942 | 0.030 |
Why?
|
| Vaccines, Synthetic | 1 | 2014 | 355 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2014 | 446 | 0.030 |
Why?
|
| Immunization | 1 | 2014 | 397 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2013 | 886 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2015 | 9180 | 0.030 |
Why?
|
| Virus Replication | 1 | 2015 | 709 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2014 | 1008 | 0.030 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2004 | 2326 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2016 | 1555 | 0.020 |
Why?
|
| Viremia | 1 | 2012 | 177 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2015 | 1732 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2012 | 621 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 1217 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2013 | 1021 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2004 | 5178 | 0.020 |
Why?
|
| Texas | 1 | 2021 | 6311 | 0.020 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 2796 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2009 | 15862 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2016 | 1818 | 0.020 |
Why?
|
| Prostate | 1 | 2014 | 1088 | 0.020 |
Why?
|
| Apoptosis | 3 | 2009 | 7591 | 0.020 |
Why?
|
| Influenza Vaccines | 1 | 2014 | 635 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2009 | 7548 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2009 | 634 | 0.020 |
Why?
|
| Lymphatic Metastasis | 2 | 2009 | 4844 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2009 | 548 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2009 | 875 | 0.020 |
Why?
|
| Protein Binding | 1 | 2014 | 3438 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2013 | 3033 | 0.020 |
Why?
|
| Cell Death | 1 | 2009 | 671 | 0.020 |
Why?
|
| Cell Movement | 1 | 2014 | 2466 | 0.020 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 2005 | 39 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 4143 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2021 | 12873 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2005 | 114 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2021 | 16273 | 0.020 |
Why?
|
| Cell Proliferation | 2 | 2009 | 7226 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2014 | 5710 | 0.020 |
Why?
|
| Topoisomerase Inhibitors | 1 | 2004 | 6 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2002 | 7789 | 0.010 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2005 | 566 | 0.010 |
Why?
|
| Tumor Burden | 1 | 2009 | 1987 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2009 | 3536 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2003 | 448 | 0.010 |
Why?
|
| Lac Operon | 1 | 2002 | 122 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2009 | 1547 | 0.010 |
Why?
|
| Precancerous Conditions | 1 | 2009 | 1058 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 2002 | 331 | 0.010 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2003 | 324 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2005 | 669 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 4367 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2002 | 644 | 0.010 |
Why?
|
| Child | 1 | 2021 | 29154 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2002 | 371 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2002 | 798 | 0.010 |
Why?
|
| Point Mutation | 1 | 2002 | 769 | 0.010 |
Why?
|
| Adolescent | 1 | 2019 | 31252 | 0.010 |
Why?
|
| Exons | 1 | 2002 | 1328 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2009 | 2967 | 0.010 |
Why?
|
| Alleles | 1 | 2002 | 2437 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2003 | 5395 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2002 | 3821 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2009 | 5319 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2004 | 9244 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 2004 | 3022 | 0.010 |
Why?
|
| Time Factors | 1 | 2004 | 12926 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2004 | 14889 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2004 | 4557 | 0.000 |
Why?
|